Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 7, 1996, Pages 2711-2718

  Pausova, Zdenka ^a   Soliman, Eric ^a   Amizuka, Norio ^a   Janicic, Natasa ^a   Konrad, Edyta M ^a   Arnold, Andrew ^b   Goltzman, David ^a   Hendy, Geoffrey N ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL TRANSFORMATION; CHROMAFFIN CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID ADENOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL;

ADENOMA; ADOLESCENT; ADULT; BASE SEQUENCE; BLOTTING, NORTHERN; DROSOPHILA PROTEINS; EXONS; FEMALE; GENE EXPRESSION; HUMANS; HYPERPARATHYROIDISM; IN SITU HYBRIDIZATION; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PARATHYROID NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; RNA-DIRECTED DNA POLYMERASE;

EID: 0029995894     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.7.2711     Document Type: Article

References (55)

1. Roth SI. 1990 The parathyroid gland. In: Silverberg SG (ed) Principles and Practice of Surgical Pathology, ed 2. New York: Churchill Livingstone; 1923-1955.
2. Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. 1988 Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med. 318:658-662.
3. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drüeke TB. 1995 Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 95:2047-2053.
4. Knudson AG. 1993 Antioncogenes and human cancer. Proc Natl Acad Sci USA. 90:10914-10921.
5. Hendy GN, Arnold A., Molecular basis of PTH overexpression. In: Bilezikian JP, Raisz LR, Rodan GA (eds) Principles of Bone Biology. San Diego: Academic Press, in press.
6. Arnold A, Kim HG, Gaz RD, et al. 1989 Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest. 83:2034-2040.
7. Motokura T, Bloom T, Kim HG, et al. 1991 A novel cyclin encoded by a bc1-linked candidate oncogene. Nature. 350:512-515.
8. Cryns VL, Thor A, Xu H-J, et al. 1994 Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 330:757-761.
9. Cryns VL, Rubio M-P, Thor AD, Louis DN, Arnold A. 1994 p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 78:1320-1324.
10. Bystrom C, Larsson C, Blomberg C, et al. 1990 Localization of the MEN 1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA. 87:1968-1972.
11. Friedman E, DeMarco L, Cejman PV, et al. 1992 Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res. 52:6804-6809.
12. Cryns VL, Yi SM, Tahara H, Gaz RD, Arnold A. 1995 Frequent allelic loss of distal chromosome 1p DNA in human parathyroid adenomas. Genes Chromosomes and Cancer. 13:9-17.
13. Carney JA, Roth SI, Heath, III, H, Sizemore GW, Hayles AB. 1980 The parathyroid glands in multiple endocrine neoplasia type 2b. Am J Pathol. 99:387-398.
14. Mulligan LM, Kwok JBJ, Healey CS, et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:458-460.
15. Donis-Keller H, Dou S, Chi D, et al. 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851-856.
16. Hofstra RMW, Landsvater I, Ceccherini I, et al. 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:375-376.
17. Mulligan LM, Ponder BAJ. 1995 Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 80:22 1989-1995.
18. Cote GJ, Whollk N, Evans D, Goepfert H, Gagel RF. 1995 RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. In: Thakker RV ed. Bailliere's Clinical Endocrinology and Metabolism. Vol 9. London: Bailliere Tindall; 603-630.
19. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai G. 1988 Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 3:571-578.
20. Santoro M, Carlomagno F, Romano A, et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 267:381-383.
21. Songyang Z, Carraway KL III, Eck MJ, et al. 1995 Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 373:536-539.
22. Beldjord C, Desclaux-Arramond R, Raffin-Sanson M, et al. 1995 The RET proto-oncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects. J Clin Endocrinol Metab. 80:2063-2068.
23. Blaugrund JE, Johns MM, Eby YJ, Ball DW, et al. 1994 RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet. 3:1895-1897.
24. Eng C, Smith DP, Mulligan LM, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet. 3:237-241.
25. Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larrson C. 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC's. Hum Mol Genet. 3:1259-1262.
26. Lindor NM, Honchel R, Khosla S, Thobodeau SN. 1995 Mutations in the RET proto-oncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab. 80:627-629.
27. Eng C, Mulligan LM, Smith DP, et al. 1995 Mutation of the RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes and Cancer. 12:209-212.
28. Balinsky BI. 1970 An Introduction to Embryology. Philadelphia: W.B. Saunders.
29. Pearse AGE, Takor-Takor T. 1979 Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. Fed Proc. 38:228-294.
30. Pearse AGE. 1990 Genesis of the neuroendocrine system. In: Friesen SR, Thomson NV (eds) Surgical Endocrinology Clinical Syndromes, ed 2. Philadelphia: JB Lippincott; 15-21.
31. Gagel RF, Tashjian, Jr, AH, Cummings T, et al. 1988 The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med. 318:478-484.
32. Bone HG, Deftos LJ, Snyder WH, Pak CYC. 1992 Mineral metabolic effects of thyroidectomy and long-term outcomes in a family with MEN 2A. Henry Ford Hosp Med J. 40:258-260.
33. Mulligan LM, Eng C, Healey CS, et al. 1993 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 6:70-74.
34. Pachnis V, Mankoo B, Constantini F. 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 119:1005-1017.
35. van Heyningen V. 1994 One gene - four syndromes. Nature. 367:319-320.
36. Santoro M, Rosati R, Grieco M, et al. 1990 The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene. 5:1595-1598.
37. Miya I, Yamamoto M, Morimoto H, et al. 1992 Expression of the ret proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A. Henry Ford Hosp Med J. 40:215-219.
38. Nakamura T, Ishizaka Y, Nagao H, Hara M, Ishikawa T. 1994 Expression of the RET proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol. 172:255-260.
39. Ausubel FM, Brent R, Kingston RE, et al. (eds). 1987 Current Protocols in Molecular Biology. New York: John Wiley & Sons.
40. Kawasaki ES. 1990 Amplification of RNA. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ. (eds) PCR Protocols. A Guide to Methods and Applications. San Diego: Academic Press; 21-27.
41. Hendy GN, Kronenberg HM, Potts, Jr, JT, Rich A. 1981 Nucleotide sequence of cloned cDNAs encoding human preproparathyroid hormone. Proc Natl Acad Sci USA. 78:7365-7369.
42. Eng C, Smith DP, Mulligan LM, et al. 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 10:509-513.
43. Higuchi R. 1989 Recombinant PCR. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ. (eds) PCR Protocols. A Guide to Methods and Applications. San Diego: Academic Press; 177-183.
44. Mansberger AR, Wei JP. 1993 Surgical embryology and anatomy of the thyroid and parathyroid glands. Surg Clin N Am. 73:727-746.
45. Gardner E, Mulligan LM, Eng C, et al. 1994 Haplotype analysis of MEN 2 mutations. Hum Mol Genet. 3:1771-1774.
46. Bolino A, Schuffenecker I, Luo Y, et al. 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 10:2415-2419.
47. Voelkel EF, Tashjian, Jr, AH, Davidoff FF, Cohen RB, Perlia CP, Wurtman RJ. 1973 Concentrations of calcitonin and catecholamines in pheochromocytomas, a mucosal neuroma and medullary thyroid carcinoma. J Clin Endocrinol Metab. 37:297-307.
48. Block MB, Roberts JP, Kadair RG, Seyfer AE, Hull SF, Nofeldt FD. 1975 Multiple endocrine adenomatosis type 2b: diagnosis and treatment. JAMA. 234:710-714.
49. Bartlett RC, Myall RWT, Bean LR, Mandelstam P. 1971 A neuropolyendocrine syndrome: mucosal neuromas, pheochromocytoma, and medullary thyroid carcinoma. Oral Surg. 31:206-220.
50. Takahashi M, Ritz J, Cooper JM. 1985 Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 42:581-588.
51. Ishizaka Y, Tahira T, Ochiai M, Ikeda I, Sugimura T, Nagao N. 1988 Molecular cloning and characterization of human ret-II oncogene. Oncogene Res. 3:193-197.
52. Ishizaka Y, Ochiai M, Tahira T, Sugimura T, Nagao M. 1989 Activation of the ret-II oncogene without a sequence encoding a transmembrane domain and transforming activity of the two ret-II oncogene products differing in carboxy-termini due to alternative splicing. Oncogene. 4:789-794.
53. Koda T. 1988 RET gene from a human stomach cancer. Hokkaido J Med Sci. 63:913-924.
54. Fusco A, Grieco M, Santoro M, et al. 1987 A new oncogene in human papillary thyroid carcinomas and their lymph-nodal metastases. Nature. 328:170-172.
55. Santoro M, Sabino N, Ishizaka Y, et al. 1993 Involvement of RET oncogene in human tumors: specificity of RET activation to thyroid tumors. Br J Cancer. 68:460-464.